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David Thomson5, Sharon F. Terry6, Béatrice de Montleau7, Diego Ardigò8, Virginie Hivert7, Kym M. Boycott9, Gareth Baynam10,11,
Petra Kaufmann1, Domenica Taruscio12, Hanns Lochmüller13, Makoto Suematsu14, Carlo Incerti15, Ruxandra Draghia-Akli16,17,
Irene Norstedt16, Lu Wang18 and Hugh J.S. Dawkins19 on behalf of the International Rare Diseases Research Consortium (IRDiRC)
The International Rare Diseases Research Consortium
(IRDiRC) was founded in 2011 with the conviction that rare
diseases research had reached a critical juncture. Proof of
principle existed that rare diseases could be diagnosed,
new treatments successfully developed and approved, and
improvements in quality and quantity of life achieved. Gov-
ernment research funders, companies, scientists, and patient
advocacy groups had all demonstrated their commitment
and effectiveness in contributing to progress in rare diseases
research. However, the work was largely atomized, with each
organization, each country, and the champions of each dis-
ease pursuing independent, often duplicative solutions. The
scale of the “rare disease problem”—thousands of rare dis-
eases, the vast preponderance of them with no approved
treatment, and decades-long diagnostic odysseys for many
patients—led to the realization that the time had arrived for
global cooperation and collaboration among themany stake-
holders active in rare diseases research, to capitalize on
these proofs of principle, andmaximize the output of rare dis-
eases research efforts around the world. IRDiRC’s initial aims
were to aid in the achievement of two overarching objec-
tives: to contribute to the development of 200 new therapies
and the means to diagnose most rare diseases by the year
2020.1 For more detailed information on the history, gover-
nance, and nascent stages of the Consortium, please refer
to the accompanying piece on the first 6 years of IRDiRC.2
Due to the remarkable global surge in activity in rare dis-
eases research over the last 6 years, including contributions
by IRDiRC, the Consortium’s 2020 goal for 200 new therapies
was achieved in early 2017—3 years ahead of schedule—
and the goal for diagnostics—the ability to diagnose most
rare diseases by 2020—is within reach; these accomplish-
ments were celebrated at the 3rd IRDiRC Conference in Paris
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in February 2017.3 The 6 years preceding this 2017 con-
ference have been truly extraordinary for the rare diseases
research community and for rare disease patients. Major
public-sector research initiatives focused in this area have
emerged or expanded in many countries, most notably from
the USNational Institutes of Health (NIH), the EuropeanCom-
mission (EC), and the newly formed Japan Agency for Med-
ical Research and Development (AMED). Engagement and
partnering among public funders, scientists, industry, and
people living with rare diseases have gone from being the
exception to commonplace. IRDiRC has been a major pos-
itive factor in raising public awareness about rare diseases,
the need for more research to address them, and for collab-
orative tools which allow ethical data sharing for and with
patients. It has also clearly led to increased investment of
public- and private-sector research funds for rare diseases,
in addition to the research funding raised by patients and
patient organizations. IRDiRC has helped to catalyze several
important initiatives that are improving collaboration among
researchers and enhancing the ability of patients to engage
as constructive partners in research.2,4
As gratifying as these developments are, those who lead
much of the global rare diseases research community are
well aware of the enormous challenges that lie ahead for
all patients living with rare diseases to receive an accurate
and timely diagnosis, to have approved treatments available,
to get access to those treatments, and to realize improve-
ments in their quality and quantity of life; in short, to be
able to live the best life possible. Although the means to
diagnose most rare diseases that are caused by mutations
in the coding genome is on track to be achieved either via
genotype–phenotype correlation or novel gene discovery, in
practice most patients with rare diseases spend years in the
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healthcare system before an accurate diagnosis is made. For
rare diseases that have yet to be defined, next-generation
genomics and improved data sharing have resulted in faster
discovery of disease gene and consequent development of
new diagnostics, although there are signs that the rate of
disease gene discovery is now slowing, as the remaining
unsolved diseases are likely more complex.5 To respond
to this subsequent level of complexity, novel approaches,
particularly ones that better address the nonprotein coding
regions of the genome, will need to be developed. There is
some cause for confidence with regard to new therapies as
the rate of rare disease therapeutic development has been
increasing. However, it remains the case that 94% of rare
diseases lack an approved treatment,6,7 that the number of
currently untreatable rare diseases that have a first treatment
approved each year remains low, and that serious inequities
remain with regard to patient access to effective treatments
even when they are available. Additionally, the present model
for recovering drug development costs from market sales
has not been proven in its application to rare diseases with
worldwide populations of hundreds or less. To address these
therapeutic discovery issues, new approaches including
data-mining and repurposing, in addition to new models for
funding drug discovery and covering treatment costs, will be
necessary for the comprehensive treatment of rare diseases
worldwide.
With this paradox in mind—the desire to celebrate
unprecedented progress but recognizing the immense need
and opportunities that remain—IRDiRC set about devis-
ing new global rare disease goals for the coming decade.
Through this year-long collaborative process, IRDiRC aimed
to set goals that would achieve all that is scientifically pos-
sible in the short term, and aggressively push the limits
of what is currently impossible in the longer term, all with
the knowledge that patients are waiting, and “Time Equals
Lives.”8
IRDiRC: 2017–2027
Process
To assure input from all stakeholders and arrive at a
short list of ambitious but achievable IRDiRC goals for
the next decade, a multistep, year-long, objectives-setting
process was implemented. Initially, ideas on critical prob-
lems in the rare diseases field and solutions to them were
solicited broadly from IRDiRC member organizations and
nonmembers represented on the IRDiRC Scientific Com-
mittees from academia, patient organizations, the bio-
pharmaceutical industry, and regulatory bodies, in each
of the three scientific focus areas: diagnostics, founda-
tional/interdisciplinary, and therapies. The hundreds of ideas
submitted were grouped and consolidated, debated online
and in-person, and then voted on to determine which were
of highest priority and need. Based on this process, a series
of potential goals were generated, along with activities to
advance the goals, and metrics to measure progress. Dur-
ing the internal IRDiRC Meeting in Paris, France in February
2017, the candidate goals, activities, and metrics were fur-
ther refined by the IRDiRC members. At the open IRDiRC
Conference that followed, the goals were presented to the
greater rare disease community for feedback, discussion,
and questions to further shape the IRDiRC vision and objec-
tives for the next decade. This vigorous, animated, and
informed session added broad public input to the goal-
setting process and in addition spurred excitement and
engagement about IRDiRC’s plans to deliver on the promise
of science for people living with rare diseases over the next
decade. Following the Meeting and Conference, the final
IRDiRC Vision and 2017–2027 Goals were formally adopted
by vote of the IRDiRC Consortium Assembly.
Framework
Given the unusually broad scope of IRDiRC—in science, con-
stituencies, and geography—the IRDiRC goal-setting pro-
cess incorporated an unusually broad series of criteria. First,
the process utilized the “SMART” criteria—that is, candidate
goals needed to be Specific, Measureable, Achievable, Real-
istic, and Timely. They also needed to be within the scope of
IRDiRC’s research mission. Lastly, they needed to be eas-
ily understood by a wide variety of stakeholders and audi-
ences, while also being bold and transformational. Therefore,
it was determined to organize the process on four levels—
Vision, Goals, Activities, and Metrics. The Vision is IRDiRC’s
overarching statement of the end state toward which all
its activities drive; the Vision is aspirational and not time-
delimited. The Goals state bold but distinct achievements
that IRDiRC commits to accomplish over the next 10 years
that will advance the realization of the Vision. The Activi-
ties are discrete, shorter-term projects IRDiRCwill perform to
advance each of the Goals; the list of Activities will continu-
ally change, depending on successes and failures of previous
Activities and evolution of the field. The Metrics will assess
and track progress of Activities over time, ensuring account-
ability and progress toward the Goals.
The new IRDiRC Vision, the IRDiRC Goals for 2017–2027,
and exemplar Activities and Metrics, follow.
The IRDiRC Vision
Enable all people living with a rare disease to receive an
accurate diagnosis, care, and available therapy within 1
year of coming to medical attention
IRDiRC is well aware of the aspirational nature of this
Vision; IRDiRC is also cognizant that some aspects of
the Vision are outside its research mission. However,
IRDiRC also believes that the Vision is achievable with all
stakeholders’ commitment, cooperation, and collaboration.
Thus, the challenge inherent in the Vision is intentional, aimed
at galvanizing the broad rare disease community, within
IRDiRC and outside it, to not only enable universal diagno-
sis and treatment, but also ensure that these interventions
reach people with rare diseases, and have the intended pos-
itive impact on their health and well-being.
The IRDiRC Goals for 2017–2027
The three Goals that IRDiRC members have committed to
achieving in the next decade to advance the realization of
the IRDiRC Vision follow, along with the rationale, challenges,
and opportunities of each.
Clinical and Translational Science
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Goal 1: All patients coming to medical attention with a
suspected rare disease will be diagnosed within 1 year
if their disorder is known in the medical literature; all
currently undiagnosable individuals will enter a globally
coordinated diagnostic and research pipeline
Recent data indicate that approximately half of the individ-
uals with a suspected rare disease are undiagnosed, while
those who have received a diagnosis wait on average 5–
6 years,9,10 and diagnostic delays of several decades have
been observed. The clinical introduction of new diagnostic
methods such as next-generation sequencing has allowed
the laboratory turnaround time to be as short as several
weeks to diagnose some of the rare diseases with a known
molecular basis. Each undiagnosed rare disease represents
an opportunity to open up a new area of biological insight,
and it follows that, as the number of novel genes and
pathogenic variants identified increases, so does the diag-
nostic yield. The time has come for researchers, clinicians,
and patients worldwide to collectively understand the etiol-
ogy of the vast number of rare diseases, make the final push
to enable the diagnosis of all rare diseases, and facilitate
access to an efficient diagnosis for patients. Within the next
decade, IRDiRC will work together to implement a system
whereby patients with a suspected rare disease of known
molecular basis will be diagnosed within 1 year of initial pre-
sentation to a medical professional instead of confronting a
years-long diagnostic odyssey. The challenges in achieving
this part of Goal 1 are principally operational, involving public
and physician awareness, efficient referral within the medical
system, and the requirement for radically more efficient shar-
ing of diagnostic expertise and data among practitioners and
researchers worldwide.
Rare disease mechanism discovery
The number of unsolved patients following whole exomes
sequencing argues that more disease genes and variants
await discovery, thus the discovery effort must be expe-
dited. So far, most of the known disease variants fall in cod-
ing regions of the genome, but much less is known, for
example, about the role of noncoding region variants and
structural variants in disease.5 This calls for approaches that
are complementary to whole exome sequencing (WES) such
as whole genome sequencing (WGS), long read technolo-
gies, and transcriptome sequencing that canmore effectively
target noncoding regions and/or structural variants. More-
over, variant interpretation still needs improvement through
developments in bioinformatics, analysis algorithms, and
data sharing. Wide acceptance of data standards and
ontologies (e.g., Human Phenotype Ontology (HPO)11
and Orphanet Rare Disease Ontology (ORDO)),12 and auto-
mated exchange of phenotypic and genomic informa-
tion via shared platforms and tools (e.g., Matchmaker
Exchange13 and RD-Connect14) should be required to trans-
form sequence information into diagnostic knowledge. Func-
tional analyses at scale will need to be developed to facilitate
variant interpretation in conjunction with data sharing.
Patient access to diagnosis
After initial presentation to a medical professional, patients
with a rare disease often spend a long time trying to find a
specialist with appropriate expertise to recognize the syn-
drome or perform the correct diagnostic test. Comprehen-
sive and easily accessible information about subspecialty
medical professionals and diagnostic laboratories can help
shorten this time. In conjunction, sequencing and analysis
costs will need to continue to drop to improve affordabil-
ity. Finally, robust data should be collected and analyzed
on diagnostic utility, clinical utility, and cost-effectiveness to
facilitate reimbursement of sequencing-based diagnosis by
more health insurance companies.
International network for undiagnosed patients
It has been shown that undiagnosed patients have an
increased chance for their diagnostic challenge to be
“solved” in a research setting where more comprehen-
sive sequencing, analysis, and data sharing can be per-
formed. It is time to establish global networks of clinical
and research laboratories to collectively tackle undiagnosed
diseases. Ideally, appropriate consents including the provi-
sion for research and data sharing should be obtained from
the outset of the clinical testing process. Samples for fur-
ther research using sequencing and other genomic methods
should be collected and stored in appropriate bioreposito-
ries. However, there is only so much that can be done without
cooperation and coordination on a larger scale. If a diagnosis
is not made after initial sequencing, then the data should be
immediately transferred to a global network of appropriate
expertise that can accept it for further study and immediate
feedback of the result. The Undiagnosed Diseases Network
International (UDNI)15—modeled after the US NIH’s Undiag-
nosed Diseases Program (UDP)—is an example of a pro-
gram established to aid in this effort. Collaboration with the
UDNI as well as UDP will bring crucial attention to com-
plex cases, where collective expertise will lead to a higher
chance of providing a much-needed diagnosis in order to
identify the best course of treatment for each patient. IRDiRC
also encourages collaboration with national programs, such
as the Japanese Initiative on Rare and Undiagnosed Dis-
eases (IRUD),16 to capitalize on additional knowledge and
data sharing with the aim of bringing diagnoses to rare dis-
eases patients.
Education of physicians and engagement of patients
To take advantage of fast-evolving technologies, estab-
lished networks, and available tools, it is necessary to
educate physicians and engage patients and families. For
example, education can be provided via courses on rare
diseases and new diagnostic methods and targeted to
various end-users, including physicians and patients, with
different levels of knowledge at the outset. Patient engage-
ment in research and clinical networks should continue to be
facilitated.
Metrics
Online Mendelian Inheritance in Man (OMIM)17 and
Orphanet18 will continue to be reliable resources for mon-
itoring newly reported diseases and disease genes. The
time it takes for a patient to be diagnosed could come from
surveys of specialty physicians, clinical labs, and patient
www.cts-journal.com
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organizations, or more targeted sampling via rare disease
networks.
Goal 2: 1000 new therapies for rare diseases will be
approved, the majority of which will focus on diseases
without approved options
Although the rate of therapy development for rare dis-
eases has been increasing, the fact remains that most rare
diseases—well over 90%—lack an approved treatment and
the number of currently untreatable rare diseases to receive a
first treatment each year remains low. The introduction of reg-
ulations, policies, and incentives dedicated to orphan drug
development has spurred significant investment in therapeu-
tic development to the benefit of rare disease patients.19
Since 2010, IRDiRC has tracked the number of orphan
medicinal products (OMPs) receiving first approval for a new
indication in the European Union and/or the United States,
and has found an increase from 15 in 2010 to more than 40 in
2014 and 2015, with a current average of 35 approvals per
year. Between 2010 and 2016, over 220 OMPs have received
first approval for a new indication in the European Union
and/or the United States. While significant, this achievement
does not negate the fact that patients with one of the thou-
sands of other rare diseases are still waiting for a therapy
to be approved for their conditions. Innovative approaches,
including clinical trial design, data and specimen collection,
clinical end points, repurposing, natural history studies, and
engaging the many players involved are necessary for expo-
nentially improving therapy development on a global scale.
Therapeutic development pipeline
Assuming a constant delivery of OMPs from the pipelines
of biopharmaceutical industries, in the next 10 years treat-
ments would become available for only 600 of the 7,000
known rare diseases. Thus, new approaches will be needed,
particularly since the current pace may not be sustained.
In 2016, only 34 new indications were approved, sug-
gesting a slowing of the development and approval pace.
Moreover, developed drugs have often clustered around
similar technologies or therapeutic approaches that will
soon have maximized their capacity to generate new thera-
peutic advances. For instance, the systemic manifestations
of several lysosomal storage disorders (LSDs) have been
quite successfully addressed by treatments based on enzy-
matic replacement through recombinant proteins containing
mannose-6-phospate residues or small molecules through
substrate inhibition, but the list of remaining LSDs to be
targeted is significantly shrinking and all these drugs leave
unaddressed the same manifestations (e.g., the central
nervous system involvement). The “lower-hanging fruits” of
easily developable indications, addressable by traditional
approaches, will likely decrease over time, leaving more
complex therapeutic targets and yet unproven technologies.
In addition to challenges specific to rare diseases, the risk-
adjusted development costs in the pharmaceutical indus-
try have witnessed an overall increase, and postregulatory
approval access challenges have become larger due to bud-
getary constraints of payers.20,21 In order to achieve the
IRDiRC goal of 1,000 new therapies in the next decade, a sig-
nificant increase in R&D productivity is needed, with a com-
pounded annual growth rate at or above 10%, thus tripling
the current rate. Moreover, the IRDiRC goal is for new orphan
drug approvals to be predominantly for diseases currently
without approved drugs. Although IRDiRC anticipates that
many of the 1,000 new approvals will be new indications for
existing agents rather than new molecular entities, scalabil-
ity and sustainability will be significant challenges, both to
the regulatory system, and to healthcare budgets. IRDiRC
includes representatives from the world’s major pharmaceu-
tical regulatory agencies and is deliberately increasing rep-
resentation from health technology assessment agencies, in
order to anticipate and mitigate these challenges.
Potential advancements in therapeutic development
This important goal can be achieved only through a dra-
matically more efficient development process driven by a
radically new approach utilizing common standards across
distinct research fields, sharing of best practices, creating
sustainable business models, and redefining the regulatory
environment. New methodologies are needed to streamline
drug development. These include early stage improvements
such as increasing the efficiency of data collection and shar-
ing, improving the understanding of disease progression and
phenotypes, improvedmethods for preclinical assessment of
safety and efficacy, and methodologies for small size clin-
ical trials. In addition, later stage advancements including
defining end points more universally suitable for measur-
ing patient’s benefit, providing medical relevance, generat-
ing regulatory benefit/risk evidence, and quantifying a prod-
uct’s economic value for payers, companies, and society
at large are essential. The emerging European Reference
Networks22 and the potential collaborations with the US Rare
Diseases Clinical Research Network23 provide an unprece-
dented opportunity for coordinating global rare diseases
research to: improve care standards, increase access to
diagnosis and treatment, increase the understanding of phe-
notypes and natural history, increase enrollment of patients
into clinical trials, and more effectively create and manage
disease registries.
Engaging patients and regulators
Placing patients at the center of clinical research, drug
development, and evaluation is increasingly recognized as
paramount to fully understanding a disease and to identi-
fying meaningful end points. Their knowledge, contribution,
empowerment, and participation are crucial to increasing the
efficiency of such efforts. Close cooperative actions with
regulators will also be indispensable, particularly via early
dialog with regulators and product development with proto-
col assistance to ensure regulations are adhered to at every
step, thus maximizing the potential outcome of a marketing
authorization. To cope with an increased volume of appli-
cations and requests of protocol assistance, a number of
changes will be necessary: streamlining the approval pro-
cess, creating collaborative review processes between regu-
lators from different jurisdictions, increasing human resource
and training programs, and potentially updating regulations
to assist in accelerating therapy development. Efforts are
already under way to streamline and align regulatory pro-
cesses across jurisdictions24; IRDiRC aims to aid and foster
Clinical and Translational Science
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such efforts, as they will ultimately contribute to the develop-
ment of new rare disease therapies. In addition to coordinat-
ing research efforts, data sharing, and patient engagement,
it is also vital to promote changes to the drug development
landscape such as new models of risk and incentive sharing
between public and private partners, systematic repurposing
of existing agents, and developing a more flexible regulatory
framework. IRDiRC is committed to work as a key enabler of
this quantum change as reflected in the vision. IRDiRC pro-
motes the development and sharing of new tools, best prac-
tices, and recommendations to inform research policies and
strategies worldwide. IRDiRC also will foster newmethods to
enable dialog between private and public research funders
and regulators with the goal of bringing about this quantum
change needed to reach the ambitious goal of developing
1,000 new therapies within the next decade.
Metrics
The number of new indications treated with medicinal prod-
ucts for rare diseases receivingmarketing authorization in the
European Union, the United States, and Japan will be the
main indicator of progress toward the 1,000 therapies goal,
based on information from the European Medicines Agency
(EMA), the US Food and Drug Administration (FDA), and
the Japanese Pharmaceuticals and Medical Devices Agency
(PMDA). A number of secondary metrics will also be devel-
oped to monitor the quality of evolution of the field, e.g., the
number of medicinal products for rare diseases with mar-
keting authorization but without orphan designation, and the
number of RDs that are addressed by these medicinal prod-
ucts.
Goal 3: Methodologies will be developed to assess the
impact of diagnoses and therapies on rare disease
patients
While faster diagnosis and increased development of new
therapies are essential, their impact on people living with rare
diseases cannot be assumed; for example, patients can ben-
efit only to the degree that they have access to the inter-
ventions, and access may or may not lead to the intended
improvement in quantity and/or quality of life. Although
IRDiRC members, representing funders, companies, patient
advocacy groups, scientists, and other stakeholders agreed
on this truism, they varied in their view of IRDiRC’s role,
as a research organization, in addressing the impact issue.
While patient advocacy group members tended to support
inclusion of impact assessment as critical IRDiRC research,
many scientific and funder members felt that this was
more the mandate of health technology assessment authori-
ties. A rich and important debate, including with numerous
stakeholders participating in the IRDiRC Conference in
February 2017, concluded with the realization that no mat-
ter what organization is charged with impact assessment, the
methods to do that assessment are currently woefully inade-
quate, and that IRDiRC therefore could and should focus on
the development of improved methodologies and tools for
performing such impact assessments.
Appropriate access to diagnosis and treatment depends
on a multitude of factors, including clinical guidelines and
recommendations; regulatory policies; pricing; insurance,
coverage, formulary, and reimbursement; and even the
awareness of healthcare providers. The efficiency and extent
of translation of diagnostic and treatment developments into
tangible outcomes and practice are currently hampered by
limited assessment of their impact on patients. Develop-
ment of robust methods to measure access, effectiveness
in real-world settings, and impact on patient outcomes will
therefore be a focus of the IRDiRC over the next decade.
Such research needs to particularly involve underdeveloped
areas worldwide, which starts by expanding our global foot-
print into more underrepresented regions and the inclusion of
such members in all activities. Equally important, as a global
health issue, IRDiRC members are committed to implement
these advances equitably to reduce existing and potential
health disparities. Such disparities include those between
Indigenous and non-Indigenous peoples, which, at its core,
requires indigenous-specific reference genetic data sets to
improve clinical diagnosis and optimize therapies.25–28 We
anticipate that this research will not only benefit rare disease
patients worldwide, but also have impacts in the wider con-
text of personalized medicine.
Measurement of impact
Assessing the impact of diagnosis remains a complex issue.
Counting the number of diagnostic tests might be relatively
simple given the various worldwide, country-specific, and
company-specific listings but is nonspecific and indirect,
speaking only to availability and not access. Quantifying the
number of people who have received a diagnosis, the length
of the diagnostic odyssey, and the impediments to diagno-
sis is, however, not straightforward. This quest goes beyond
the mandate of a single clinical or research team. Aggre-
gating this information requires a multidisciplinary and multi-
stakeholder approach that must navigate the continuum from
clinical research to healthcare services in multiple systems
and cultures. Thus, measuring the impact of diagnosis may
include such items as quantitative and statistical analysis,
assessment of quality of life, and/or economic dissection of
repercussions on medical care.
Assessing the impact of treatment is also largely limited to
regulated therapies, since these are easier to count. It has
been suggested that other types of treatments or interven-
tions, such as nonpharmaceutical approaches, physical and
behavioral therapies, and/or devices may be as valuable to
patients as “drugs,” but these are generally neglected when
considering impact. Similarly, research into healthcare sys-
tem optimization and the implementation of recommenda-
tions to improve its functions may have an important impact
on patients’ outcomes and health.
The use of existing tools and platforms, e.g., the NIH
Genetic Testing Registry,29 and RARE-Bestpractices,30 that
help develop rigorous process and qualitative markers for
the evaluation of the diagnostic and modes of care should
be factored into any methodology development. The fun-
ders should engage in identification and financial support
of research projects that will tackle the complexities around
the measurement of health outcomes. Research in health
systems, economics, and ethical frameworks should also
be promoted. Furthermore, IRDiRC may consider how to
engage appropriate stakeholders in healthcare systems to
www.cts-journal.com
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ensure that any methods developed could be recognized
rapidly, and applied at both the national and international lev-
els.
CONCLUSION
The members of IRDiRC and, more important, their organi-
zations, have committed themselves to an ambitious set of
10-year goals that will advance the realization of the IRDiRC
vision of prompt and accurate diagnosis, effective treatment,
and amelioration of illness for all people living with rare dis-
eases. In an ambitious andmultifaceted project like IRDiRC’s,
coordination and monitoring of progress will be essential;
these will be performed by the IRDiRC Committees and Sci-
entific Secretariat. The Committees and their Task Forces will
promote activities to advance the goals, and metrics will be
applied to monitor progress toward the goals. Some may
question whether the costs of IRDiRC’s vision can be jus-
tified, given the low prevalence of these disorders. We, the
leadership of IRDiRC, believe that, to the contrary, the global
community cannot afford not to achieve these goals, and the
resources the member organizations are committing to rare
diseases research to realize the IRDiRC vision testify to this
conviction. On a purely financial level, the cost to health sys-
tems of caring for people whose rare diseases are undiag-
nosed or untreatable are disproportionate and growing. On
a human level, we believe that every person with an illness,
whether rare or common, has the same right to a diagnosis
and treatment, and that the contributions to humanity of rare
disease patients are well beyond our imagining. We are all
familiar with how people living with HIV/AIDS, once an undi-
agnosable, untreatable rare disease, are continuing to enrich
the human family in innumerable ways, and how much the
work to diagnose and treat HIV/AIDS taught us about human
biology and other diseases. This is our vision for the millions
of people living with the thousands of other rare diseases.
As leaders of the global rare diseases community in the
public and private sectors, we are under no illusions about
the challenges to achieving our new goals by 2027. How-
ever, we are equally aware of the epochal advances in rare
diseases science and medicine over the last decades, the
evolution of a culture of collaboration, teamwork, and com-
mon cause that now unites the rare disease community, and
the reality that the pace of progress is positioned to acceler-
ate. These are goals that can only be achieved with funda-
mental changes in the conduct and sharing of science, and
application of that science as rapidly as possible to advance
the care of rare disease patients—changes IRDiRCmembers
have committed to catalyze. We believe that these goals are
eminently achievable over the next decade—but only with
continued commitment to scientific excellence, rapid and
ubiquitous sharing of approaches and data and resources,
and continued monitoring of progress and constant reevalu-
ation of direction based on new data. IRDiRC’s is a rigorous,
noble—and achievable—vision, which we believe will bring
out the best in science, in medicine, and in ourselves. We
welcome new members, who share our vision and commit-
ment to action, to join us. And we look forward to updating
the community on our progress.
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